openPR Logo
Press release

Detailed Study of Depression Screening/Mental Health Market Demand and Profit by 2023

02-09-2018 06:31 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Detailed Study of Depression Screening/Mental Health Market

Depression and mental health are the significant medical problems over the globe. Expanding pervasiveness of different mental issue, social and ecological changes, and changing way of life are real drivers for the market development. Rising financing for R&D and clinical trials are additionally driving the development for Depression Screening/Mental Health Market. Expanding attention to disarranges and medicines, quick selection of new treatments and medications, and mechanical progression are key drivers for the market. The Global Depression Screening/Mental Health market is growing at the CAGR of ~4.5% during the forecast period and expected to reach US$ 11245.6 million by 2023.

Competitive Landscapes:

Some of the key players in this market are: Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan), Pfizer Inc. (US), and others.

Access Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/3806 .

Segments:

Global depression screening/mental health market has been segmented on the basis of disorder which comprises of anxiety, mood disorders, depression, bipolar behavior, psychosis, eating disorders, impulse control & addiction disorders, personality disorders, stress response syndromes, dissociative disorder, somatic symptom disorder, factitious disorder, and others. Anxiety is further sub-segmented into Generalized Anxiety Disorder (GAD), panic disorder, phobias, Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD). Mood disorder is further sub-segmented into dysthymia, substance-induced mood disorder, major depression, and others. Depression is further sub-segmented into atypical depression, chronic depression, melancholic depression, catatonic depression, Seasonal affective disorder (SAD), and others. Bipolar disorder is further sub-segmented into bipolar I disorder, bipolar II disorder, cyclothymic disorder, and others. Psychotic disorder is further sub-segmented into schizophrenia, delusional disorder, and others. Eating disorder is further sub-segmented into anorexia nervosa, binge eating disorder, bulimia nervosa, and others. Impulse control and addiction disorder is further sub-segmented into intermittent explosive disorder, pyromania, kleptomania, and others. Personality disorders include various traits such as emotional & impulsive, suspicious, anxious, and others.

Check Attractive Discount @ https://www.marketresearchfuture.com/check-discount/3806 .

Dissociative disorder is sub-segmented into dissociative amnesia, dissociative identity disorder, depersonalization- derealization disorder, and others. Somatic symptom disorder somatization disorder, conversion disorder, hypochondriasis, factitious disorder, body dysmorphic disorder, and others. Factitious disorder is further sub-segmented into factitious disorder with mostly psychological symptoms, factitious disorder with mostly physical symptoms, factitious disorder with both psychological and physical symptoms, and others.

On the basis of diagnosis, the market has been segmented into psychological test, Lab tests, Depression Screening Tests and others. Psychological test is further sub-segmented into intelligence tests, attitude tests, personality tests, achievement tests, and others. Lab tests sub-segmented into blood tests, CT scan or MRI of the brain, Electroencephalogram (EEG), Electrocardiogram (ECG). Depression Screening Tests includes Patient Health Questionnaire-10 (PHQ-10), Beck Depression Inventory (BDI), Zung Self-Rating Depression Scale, Center for Epidemiologic Studies-Depression Scale (CES-D), and Hamilton Rating Scale for Depression (HRSD).

On the basis of treatment, the market has been segmented into medication, psychotherapy, brain-stimulation treatments, hospitalization, substance abuse treatment, and others. Medication includes anti-anxiety medications, antidepressants, antipsychotic medications, mood-stabilizing medications, opioid antagonists, atypical neuroleptics, glutamatergic agents, and others. Psychotherapy is further sub-segmented into cognitive and behavioural therapies, humanistic therapies, psychoanalytical and psychodynamic therapies, and others. Brain-stimulation treatments includes repetitive Transcranial Magnetic Stimulation (rTMS), Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and others.

On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

Ask to Expert @ https://www.marketresearchfuture.com/enquiry/3806 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Detailed Study of Depression Screening/Mental Health Market Demand and Profit by 2023 here

News-ID: 937654 • Views:

More Releases from Market Research Future

Blood Transfusion Diagnostics Market Industry Analysis by Demand, Size, Share, Growth, Key Players, Trends, Revenue and Forecast Till 2032
Blood Transfusion Diagnostics Market Industry Analysis by Demand, Size, Share, G …
The Blood Transfusion Diagnostics Market plays a pivotal role in ensuring the safety and efficacy of blood transfusions, a critical component of modern healthcare. This market encompasses a variety of diagnostic tools and technologies designed to assess and manage blood compatibility between donors and recipients. Key components include blood grouping and typing, infectious disease screening, and antibody detection. The market addresses the increasing demand for accurate and timely diagnostics to
1 Hexene Market size, Scope, Growth Opportunities, Trends by Manufacturers and Forecast to 2032
1 Hexene Market size, Scope, Growth Opportunities, Trends by Manufacturers and F …
1-Hexene, a key chemical intermediate primarily used in the production of polyethylene, is experiencing a significant surge in demand globally. This demand is driven by several factors, including the growing need for high-density polyethylene (HDPE) and linear low-density polyethylene (LLDPE) in various industries such as packaging, construction, and automotive. The 1 Hexene Market is estimated at US$ 0.142 billion in 2024 and is forecasted to increase rapidly at a CAGR of
Hydroxypropyl Methylcellulose Capsules Market Surge to Witness Huge Demand at a CAGR of 9.40% during the forecast period 2032
Hydroxypropyl Methylcellulose Capsules Market Surge to Witness Huge Demand at a …
Hydroxypropyl Methylcellulose (HPMC) capsules are a popular choice in the pharmaceutical and nutraceutical industries due to their versatility, safety, and stability. These capsules are derived from cellulose, a natural polymer, and are widely used for encapsulating a variety of drugs, supplements, and vitamins. The HPMC capsules market has been experiencing steady growth over the years, driven by several key factors. Hydroxypropyl Methylcellulose Capsules Market was valued at USD 0.420 Billion in
Skincare Market Size, Share, Trends, Analysis, Demand 2023-2032
Skincare Market Size, Share, Trends, Analysis, Demand 2023-2032
The Skincare Market was valued at USD 7.15 Billion in 2022. It is forecasted to increase from USD 7.54 Billion in 2023 to USD 11.58 Billion by 2032, demonstrating a compound annual growth rate (CAGR) of 5.51% between 2023 and 2032. The comprehensive scope and research methodology of the Skincare Market report lay the foundation for a detailed and insightful analysis of the industry. The report's scope encompasses a broad spectrum,

All 5 Releases


More Releases for Depression

Increase in the prevalence of anxiety disorders and depression is bolstering the …
The research report "Global Anxiety Disorders and Depression Treatment Market: By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2028." The global anxiety disorders and depression treatment market size was valued at USD 8.2 Bn in the year
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per
Depression Cannot Hit A Moving Target
Cottonwood Heights, Utah, Mar 12, 2020 -- Depression can't hit a moving target. That was a phrase to live by for Chelsea Hansen. She was full of life and love, and she had big goals. But soon she was to discover that life doesn't turn out the way she planned. Behind the Fake Smile is a fictional book based on real-life experiences. It's the story of how Chelsea navigates a world
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive
Depression Therapeutics Market Forecast till 2025
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. Antidepressants cover a wide range of drug categories, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants
Depression Drug Market: Global Depression Drug Forecast Will Reach $16.8 billion …
Zion Market Research has published a new report titled “Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020” According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50%